Results 61 to 70 of about 591,821 (395)
Glucocorticoids for treating paediatric pulmonary hypertension: A novel use for a common medication [PDF]
, 2017 Laboratory investigations have shown the role of inflammation in the pathogenesis of pulmonary hypertension and improvement after anti-inflammatory drugs.
Aggarwal, Manish, Grady, Ronald M
core +2 more sources
Pulmonary Circulation, 2022 Treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in Latin America differs between countries, with regard to disease etiology, health insurance coverage, and drug availability.
Mauricio Orozco‐Levi +11 more
doaj +1 more source
The role of endothelin-1 in pulmonary arterial hypertension. [PDF]
, 2014 Pulmonary arterial hypertension (PAH) is a rare but debilitating disease, which if left untreated rapidly progresses to right ventricular failure and eventually death. In the quest to understand the pathogenesis of this disease differences in the profile,
Chester, AH, Yacoub, MH
core +1 more source
Adult congenital heart care in the COVID-19 era, and beyond: A call for actionKey Points
International Journal of Cardiology Congenital Heart Disease, 2020 While virus epidemics are nothing new to man, the scale, speed of global spread and immediacy of the COVID-19 pandemic have been truly unprecedented [1].
Michael A. Gatzoulis +8 more
doaj +1 more source
Novel signaling pathways in pulmonary arterial hypertension (2015 Grover Conference Series) [PDF]
, 2016 The proliferative endothelial and smooth muscle cell phenotype, inflammation, and pulmonary vascular remodeling are prominent features of pulmonary arterial hypertension (PAH).
Awad, Keytam S. +3 more
core +1 more source
Current and future treatments of pulmonary arterial hypertension
British Journal of Pharmacology, 2020 Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin, and NO pathways has significantly improved outcomes. However, for the vast
N. Sommer +8 more
semanticscholar +1 more source
Idiopathic pulmonary arterial hypertension [PDF]
Disease Models & Mechanisms, 2010 Despite improved understanding of the pathobiology of pulmonary arterial hypertension (PAH), it remains a severe and progressive disease, usually culminating in right heart failure, significant morbidity and early mortality. Over the last decade, some major advances have led to substantial improvements in the management of PAH.
Amy L, Firth +2 more
openaire +2 more sources
Pulmonary hypertension associated with neurofibromatosis type 2
Pulmonary Circulation, 2021 Although precapillary pulmonary hypertension is a rare but severe complication of patients with neurofibromatosis type 1 (NF1), its association with NF2 remains unknown.
Hirohisa Taniguchi +9 more
doaj +1 more source
Perivascular Inflammation in Pulmonary Arterial Hypertension
Cells, 2020 Perivascular inflammation is a prominent pathologic feature in most animal models of pulmonary hypertension (PH) as well as in pulmonary arterial hypertension (PAH) patients.
Yijie Hu +3 more
semanticscholar +1 more source
FEBS Open Bio, EarlyView.Chemotherapies such as doxorubicin can have toxic effects on healthy cardiovascular/heart tissue. Following up on a doxorubicin toxicity study in mice without tumors where nitrate water was cardioprotective (lessened toxicity), this study with tumor‐bearing mice undergoing doxorubicin treatment showed no negative effect of nitrate and nitrite on drug ...
Rama D. Yammani +7 more
wiley +1 more source